Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Eosinophilic Gastritis
NCT03473977Phase 3Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic gastritis (EG) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Percent of Patients in Histological Remission (<30 Eos/Hpf) at 12 weeks. Started Apr 2018; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic gastritis (EG)
Beyond the preview
Go deeper on NCT03473977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473977.